PAK: An essential motif for forming β-turn structures and exhibiting the thrombolytic effect of P6A and its analogs

Biochemistry and Cell Biology

Volumn 85, Issue 6, 2007, Pages 730-740

  Zhao, Ming ^a   Jia, Xin ^b   Wang, Chao ^b   Li, Qin ^b   Zhou, Kexiang ^a   Wang, Lili ^c   Liu, Hu ^c   Peng, Shiqi ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

turn; Fibrinolysis; Peptide 6A, NMR structure; Plasminogen; Thrombolysis

Indexed keywords

FIBRINOLYSIS; PLASMINOGENS; THROMBOLYSIS; THROMBOLYTIC ACTIVITIES;

BIOACTIVITY; MOLECULAR STRUCTURE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SYNTHESIS (CHEMICAL);

PEPTIDES;

ALANYLARGINYLPROLYLALANYLLYSINE; AMINO ACID; PLASMINOGEN; PROLYALANYLLYSINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; FIBRINOLYSIS; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN CONFORMATION; PROTEIN MOTIF; PROTEIN STRUCTURE; RAT; THROMBUS;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; BLOOD COAGULATION; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; MALE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN STRUCTURE, SECONDARY; RABBITS; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; TEMPERATURE; TIME FACTORS;

EID: 38849090525     PISSN: 08298211     EISSN: None     Source Type: Journal    
DOI: 10.1139/O07-143     Document Type: Article

References (52)

1. Anderson, P.G., Saldeen, K., and Saldeen, T.G. 1983. A fibrin(ogen) derived pentapeptide induces vasodilation, prostacyclin release and an increase in cyclic AMP. Thromb. Res. 30: 213-218. doi:10.1016/0049-3848(83)90074- 9.
2. Banerjee, A., Chisti, Y., and Banerjee, U.C. 2004. Streptokinase - a clinically useful thrombolytic agent. Biotechnol. Adv. 22: 287-307. doi:10.1016/j.biotechadv.2003.09.004.
3. Belew, M., Gerdin, B., Porath, J., and Saldeen, T.G. 1978. Isolation of vasoactive peptides from human fibrin and fibrinogen degraded by plasmin. Thromb. Res. 13: 983-994. doi:10.1016/0049-3848(78)90227-X.
4. Belew, M., Gerdin, B., Lindeberg, G., Porath, J., Saldeen, T., and Wallin, R. 1980a. Structure-activity relationships of vasoactive peptides derived from fibrin or fibrinogen degraded by plasmin. Biochim. Biophys. Acta, 621: 169-178.
5. Belew, M., Gerdin, B., Larsson, L.E., Lindeberg, G., Ragnarsson, U., Saldeen, T., and Wallin, R. 1980b. Structure-activity studies on synthetic analogs to vasoactive peptides derived from human fibrinogen. Biochim. Biophys. Acta, 632: 87-94.
6. Brunger, A.T. 1993. X-PLOR Version 3.1, University Press, New Haven, CT.
7. Chou, K.C., and Blinn, J.R. 1997. Classification and prediction of beta-turn types. J. Protein Chem. 16: 575-595. doi:10.1023/A: 1026366706677.
8. Choudhury, D., Thompson, A., Stojanoff, V., Langerman, S., Pinkner, J., Hultgren, S.J., and Knight, S. 1999. X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli. Science, 285: 1061-1066. doi:10.1126/science.285.5430.1061.
9. Dechantsreiter, M.A., Planker, E., Mathä, B., Lohof, E., Hölzemann, G., Jonczyk, A., Goodman, S., and Kessler, H. 1999. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J. Med. Chem. 42: 3033-3040. doi:10.1021/jm970832g.
10. Dejana, E., Villa, S., and Gaecano, G. 1982. Bleeding time in rats: a comparison of different experimental conditions. Thromb. Haemost. 48: 108-111.
11. Deo, R.C., Groft, C.M., Rajashankar, K.R., and Burley, S.K. 2002. Recognition of the rotavirus mRNA 3′ consensus by an asymmetric NSP3 homodimer. Cell, 108: 71-81. doi:10.1016/S0092-8674(01)00632-8.
12. Dias, J.M., Than, M., Humm, A., Huber, R., Bourenkov, G., Bartunik, H., et al. 1999. Crystal structure of the first dissimilatory nitrate reductase at 1.9 Å solved by MAD methods. Structure (Lond.), 7: 65-79.
13. Enroth, C., Neujahr, H., Schneider, G., and Lindqvist, Y. 1998. The crystal structure of phenol hydroxylase in complex with FAD and phenol provides evidence for a concerted conformational change in the enzyme and its cofactor during catalysis. Structure, 6: 605-617. doi:10.1016/S0969-2126(98)00062- 8.
14. Fukai, S., Nureki, O., Sekine, S., Shimada, A., Tao, J., Vassylyev, D.G., and Yokoyama, S. 2000. Structural basis for double-sieve discrimination of L-valine from L-isoleucine and L-threonine by the complex of tRNA(Val) and valyl-tRNA synthetase. Cell, 103: 793-803. doi:10.1016/S0092-8674(00)00182-3.
15. Gerdin, B., and Saldeen, T.G. 1978. Effect of fibrin degradation products on microvascular permeability. Thromb. Res. 13: 995-1006. doi:10.1016/0049-3848(78)90228-1.
16. Hellebrekers, B.W., Trimbos-kemper, T.C., Trimbos, J.B., Emeis, J.J., and Kooistra, T. 2000. Use of fibrinolytic agents in the prevention of postoperative adhesion formation. Fertil. Steril. 74: 203-212. doi:10.1016/S0015-0282(00)00656-7.
17. Hutchinson, E.G., and Thronton, J.M. 1994. A revised set of potentials for beta-turn formation in proteins. Protein Sicence, 3: 2207-2216.
18. Hynes, R.O. 1992. Integrins: versatility, modulation, and signaling in cell adhesion. Cell, 69: 11-25. doi:10.1016/0092-8674(92)90115-S.
19. Kabsch, W., and Sander, C. 1983. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers, 22: 2577-2637. doi:10.1002/bip.360221211.
20. Kai, Y., Matsumura, H., Inoue, T., Terada, K., Nagara, Y., Yoshinaga, T., et al. 1999. Three-dimensional structure of phosphoenolpyruvate carboxylase: a proposed mechanism for allosteric inhibition. Proc. Natl. Acad. Sci. U.S.A. 96: 823-828. doi:10.1073/pnas.96.3.823.
21. Khan, I.A., and Gowda, R.M. 2003. Clinical perspectives and therapeutics of thrombolysis. Int. J. Cardiol. 91: 115-127. doi:10.1016/S0167-5273(03) 00019-6.
22. Kuntz, I.D. 1972. Tertiary structure in carboxypeptidase. J. Am. Chem. Soc. 94: 8568-8572. doi:10.1021/ja00779a046.
23. Levitt, M., and Chothia, C. 1976. Structural patterns in globular proteins. Nature, 261: 552-558. doi:10.1038/261552a0.
24. McClung, W.G., Clapper, D.L., Anderson, A.B., Babcock, D.E., and Brash, J.L. 2003. Interactions of fibrinolytic system proteins with lysine-containing surfaces. J. Biomed. Mater. Res. A, 66: 795-801. doi:10.1002/jbm.a.10017.
25. Mehta, J.L., Nichols, W.W., and Saldeen, T.G. 1989. Effects of peptide 6A on coronary blood flow dynamics in canine coronary thrombosis. J. Cardiovasc. Pharmacol. 13: 803-811.
26. Nichols, W.W., Nicolini, F.A., Saldeen, T.G., and Mehta, J.L. 1991. Combined thrombolytic effects of tissue-plasminogen activator and a fibrinogen-degradation product peptide 6A or iloprost. J. Cardiovasc. Pharmacol. 18: 231-236. doi:10.1097/00005344-199108000-00009.
27. Nilges, M., Clore, G.M., and Gronenborn, A.M. 1988. Determination of three-dimensional structures of proteins from interproton distance data by hybrid distance geometry-dynamical simulated annealing calculations. FEBS Lett. 229: 317-324. doi:10.1016/0014-5793(88)81148-7.
28. Pellecchia, M., Guntert, P., Glocshuber, R., and Wüthrich, K. 1998. NMR solution structure of the periplasmic chaperone FimC. Nat. Struct. Biol. 5: 885-890. doi:10.1038/2325.
29. Peng, J.R., Qiao, Y., and Yao, X. 1995. Chinese J. Med. Chem. 5, 134. Chem. Abstr. 124: 170633e.
30. Petersen, L.C., and Suenson, E. 1986. Trinitrobenzoylated poly(D-lysine) as a stimulator of interactions between plasminogen, plasmin, and tissue-type plasminogen activator. Biochim. Biophys. Acta, 883: 313-325.
31. Proctor, R.R., and Rapaport, S.I. 1961. The partial thromboplastin time with kaolin.A simple screening test for first stage plasma clotting factor deficiencies Am. J. Clin. Pathol. 36: 212-219.
32. Qu, C., Akanuma, S., Tanaka, N., Moriyama, H., and Oshima, T. 2001. Design, X-ray crystallography, molecular modelling and thermal stability studies of mutant enzymes at site 172 of 3-isopropylmalate dehydrogenase from Thermus thermophilus. Acta Crystallogr. D Biol. Crystallogr. 57: 225-232. doi:10.1107/S0907444900017388.
33. Rijken, D.C., and Sakharov, D.V. 2001. Basic principles in thrombolysis: regulatory role of plasminogen. Thromb. Res. 103(Suppl. 1): S41-S49. doi:10.1016/S0049-3848(01)00296-1.
34. Rose, G.D. 1978. Prediction of chain turns in globular proteins on a hydrophobic basis. Nature, 272: 586-590. doi:10.1038/272586a0.
35. Rose, G.D., and Roy, S. 1980. Hydrophobic basis of packing in globular proteins. Proc. Natl. Acad. Sci. U.S.A. 77: 4643-4647. doi:10.1073/pnas.77.8.4643.
36. Rotundi, K.S., and Gierasch, L.M. 2006. Natural polypeptide scaffolds: beta-sheets, beta-turns, and beta-hairpins. Peptide Sci. 84: 3-22. doi:10.1002/bip.20390.
37. Rouf, S.A., Moo-Young, M., and Chisti, Y. 1996. Tissue-type plasminogen activator: characteristics, applications and production technology. Biotechnol. Adv. 14: 239-266. doi:10.1016/0734-9750(96)00019-5.
38. Saldeen, T., Ryan, J.W., and Berryer, P. 1981. A peptide derived from fibrin(ogen) inhibits angiotensin converting enzyme and potentiates the effects of bradykinin. Thromb. Res. 23: 465-470. doi:10.1016/0049-3848(81)90208- 5.
39. Saldeen, K., Nichols, W., Lawson, D., Anderson, R., Saldeen, T., and Mehta, J. 1991a. Fibrin(ogen) degradation product peptide 6A increases femoral artery blood flow in dogs. Acta Physiol. Scand. 142: 339-344.
40. Saldeen, K., Nichols, W., Nichols, F., and Mehta, J. 1991b. Effect of L-arginine and an arginine-containing pentapeptide on canine femoral arterial blood flow. Ups. J. Med. Sci. 96: 113-118.
41. Saldeen, K., Lawson, D.L., and Mehta, J.L. 1991c. Angiotensin converting enzyme inhibitors potentiate the vasorelaxant effect of fibrinogen-derived peptide 6A. Thromb. Res. 61: 81-85. doi:10.1016/0049-3848(91)90170-2.
42. Satoh, A., Kim, J.K., Miyahara, I., Devreese, B., Vandenberghe, I., Hacisalihoglu, A., et al. 2002. Crystal structure of quinohemoprotein amine dehydrogenase from Pseudomonas putida. Identification of a novel quinone cofactor encaged by multiple thioether cross-bridges. J. Biol. Chem. 277: 2830-2834. doi:10.1074/jbc.M109090200.
43. Shindo, H., Iwaki, T., Ieda, R., Kurumizaka, H., Ueguchi, C., Mizuno, T., et al. 1995. Solution structure of the DNA binding domain of a nucleoid-associated protein, H-NS, from Escherichia coli. FEBS Lett. 360: 125-131. doi:10.1016/0014-5793(95)00079-O.
44. Wang, A.C., and Bax, A. 1996. Determination of the backbone dihedral angles in human ubiquitin from reparametrized empirical Karplus equations. J. Am. Chem. Soc. 118: 2483-2494. doi:10.1021/ja9535524.
45. Wardlaw, J.M., Warlow, C.P., and Counsell, C. 1997. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet, 350: 607-614. doi:10.1016/S0140-6736(97)03022-5.
46. Wayne, P.A. 1998.Collection, transport and processing of blood specimens for coagulation testing and general performance of coagulation assays. Approved guideline H21-A2. 3rd ed. National Committee for Clinical Laboratory Standards.
47. Wu, Y.F., Zhao, M., Wang, C., and Peng, S.Q. 2002. Synthesis and thrombolytic activity of pseudopeptides related to fibrinogen fragment. Bioorg. Med. Chem. Lett. 12: 2331-2333. doi:10.1016/S0960-894X(02)00403-1.
48. Wuthrich, K., Billeter, M., and Braun, W. 1983. Pseudo-structures for the 20 common amino acids for use in studies of protein conformations by measurements of intramolecular proton-proton distance constraints with nuclear magnetic resonance. J. Mol. Biol. 169: 949-961. doi:10.1016/S0022- 2836(83)80144-2.
49. Zhao, M., Peng, S.Q., Cai, M.S., Xu, Y.F., Zhang, L., and Tang, C.S. 1994. The structure modifications and functions of P6A. Prog. Nat. Sci. 4: 334-340.
50. Zhao, M., Lin, N., Wang, C., and Peng, S.Q. 2003a. Thrombolytic activity of fibrinogen fragment related cyclopeptides. Bioorg. Med. Chem. Lett. 13: 961-964. doi:10.1016/S0960-894X(02)01072-7.
51. Zhao, M., Wang, C., Yang, J., Liu, J.Y., Xu, Y.X., Wu, Y.F., and Peng, S.Q. 2003b. Identification, synthesis and bioassay for the metabolite of P6A. Bioorg. Med. Chem. 11: 4813-4820.
52. Zhao, M., Wang, C., Wu, Y.F., Zhou, K.X., and Peng, S.Q. 2004. Synthesis and thrombolytic activity of carboline-3-carboxylic acid modified metabolites of ARPAK. Prep. Biochem. Biotechnol. 34: 55-74.